Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243878 | 0.95 | PTGS2 (0.38) | PTGS2PTGS1ALDH1A1ALOX15HDAC3 | |
| SCHEMBL4369881 | 0.91 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1ALOX15GALR3 | |
| SCHEMBL4374476 | 0.85 | PTGS2 (0.36) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL21682593 | 0.83 | PTGS2 (0.36) | PTGS2PTGS1HDAC3HDAC1HDAC2 | |
| SCHEMBL457413 | 0.82 | PTGS2 (0.47) | PTGS2PTGS1ALDH1A1CA1CA2 | |
| SCHEMBL21682594 | 0.82 | PTGS2 (0.38) | PTGS2PTGS1HDAC3HDAC1HDAC2 | |
| SCHEMBL12889840 | 0.80 | PTGS2 (0.38) | PTGS2PTGS1HDAC3HDAC1HDAC2 | |
| SCHEMBL12889841 | 0.80 | PTGS2 (0.38) | PTGS2PTGS1HDAC3HDAC1HDAC2 | |
| SCHEMBL12889838 | 0.80 | PTGS2 (0.38) | PTGS2PTGS1HDAC3HDAC1HDAC2 | |
| SCHEMBL12889839 | 0.80 | PTGS2 (0.38) | PTGS2PTGS1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622502-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2009-11-24 | — | — | US | disclosed |
| US-20080242722-A1 | Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events | DUFRESNE CLAUDE | 2008-10-02 | — | — | US | disclosed |
| US-20080227758-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5h)-Furanones as Cyclooxygenase-2 Inhibitors | BERTHELETTE CARL | 2008-09-18 | — | — | US | disclosed |
| EP-1711457-A4 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2008-01-09 | — | — | EP | disclosed |
| EP-1711454-A4 | COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS | MERCK FROSST COMPANY (CA) | 2007-04-04 | — | — | EP | disclosed |
| EP-1711454-A1 | COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS | Merck Frosst Company (CA) | 2006-10-18 | — | — | EP | disclosed |
| EP-1711457-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Company (CA) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005070874-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070868-A1 | COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS | MERCK FROSST COMPANY (CA) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242722-A1 | Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885ALDH1A1 372/4885 |
| US-20080227758-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5h)-Furanones as Cyclooxygenase-2 Inhibitors | PTGIS, PTGS1, PTGS2 | PTGS2 3/4885PTGS1 2/4885ALDH1A1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.